ACE阻害トリペプチドLL-Xの構造-活性関係と分子相互作用メカニズム
Cuicui Yang1, Mengmeng Cai1, Zhengkun Ma1
1Guangxi Key Laboratory for Polysaccharide Materials and Modifications, School of Chemistry and Chemical Engineering, Guangxi Minzu University, Nanning 530006, China.
Bioorganic chemistry
|August 30, 2025
まとめ
C末端アミノ酸は,アニオテンシン変換酵素 (ACE) 抑制ペプチドの活性に有意な影響を及ぼします. 抗高血圧ペプチドの設計におけるチロシンの重要な役割を強調する.
科学分野:
- 生物化学
- 薬理学について
- 薬物の発見
背景:
- 血管新生変換酵素 (ACE) 阻害剤は高血圧の管理に不可欠です.
- ACE阻害ペプチドの分子相互作用を理解することは,抗高血圧薬の開発に役立ちます.
- カセイン由来トライペプチドLeu-Leu-Tyr (LLY) は,ACE阻害特性を示しています.
研究 の 目的:
- ACE抑制ペプチドの活性に対するC末端アミノ酸置換の影響を調査する.
- 新しいペプチド変種 (LLF,LLP) とLLYのACE阻害運動と結合機構を比較する.
- 効果的なACE阻害ペプチドの設計のための理論的基礎を提供する.
主な方法:
- 新しいペプチド変種である Leu-Leu-Phe (LLF) と Leu-Leu-Pro (LLP) の合成
- ACE抑制作用の測定 (IC50の決定)
- 酵素運動分析 (ラインウィーバー-ブルックプロット).
- 分子ドッキングと 分子ダイナミクスシミュレーション
- ペプチド-ACE相互作用とタンパク質構造の変化を分析する多スペクトル技術.
主要な成果:
- LLF (IC50 = 168. 57 ± 5. 11 μM) とLLP (IC50 = 96. 64 ± 2. 93 μM) は,LLY (IC50 = 44. 16 ± 2. 45 μM) よりも著しく低いACE抑制活性を示した.
- LLYと同様に,LLFとLLPは非競争性のACE阻害剤として作用した.
- LLYはACEにおけるより大きなタンパク質構造障害を誘発し,LLFとLLPと比較してより高い抑制活性と相関する.
結論:
- LLYのC末端のチロシンは,その強力なACE阻害作用のために重要である.
- C端のアミノ酸特性は,トリペプチドACE阻害剤の有効性に大きな影響を与えます.
- この研究は,新しい抗高血圧ペプチドの合理的な設計のための基礎的な洞察を提供します.
さらに関連する動画
関連する概念動画
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
645
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
645
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.2K


